DIAMEDICA THERAPEUTICS INC

DMACNASDAQ

🏆 #2898 by market capEarnings Nov 11US Equity

$6.85▼ $0.02 (−0.36%)

Live

1h▼ 1.3%

24h▼ 0.4%

7d▲ 2.5%

14d▲ 8.3%

30d▼ 8.7%

1y▲ 31.6%

🏦Market Cap

$369M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $6.82 – $6.88
52-Week Range: $4.39 – $10.42
Volume: $2.13B
Avg Volume: $2.24B
Shares Outstanding: 53.9M
Next Earnings: Sep 3, 2026

Fundamentals Snapshot

Annual Revenue: $86M
Last Q Revenue: $20M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.71
Dividend Yield: —

Why Investors Own DMAC

✓High-growth profile — revenue up -8.7% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$86M▼ −6.7% YoY

Gross Margin (TTM)

28.1%▲ +2.3% YoY

Operating Income (TTM)

$21M▼ −6.7% YoY

Free Cash Flow (TTM)

$5M▼ −6.7% YoY

About DIAMEDICA THERAPEUTICS INC

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.

🦦

Otter Score Breakdown

ⓘ

💎Quality★★★★★

🚀Growth★★★★★

⚖️Valuation★★★★★

⚡Momentum★★★★★

Overall Score

Weak

59/100

Analyst Ratings

ⓘ

Consensus

Buy

11 analysts

Strong Buy2

Buy8

Hold1

Sell0

Strong Sell0

Ratings as of Aug 2026

Latest News & Updates

SeekingAlpha·1d ago

DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript

DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call August 11, 2026 8:00 AM EDTCompany ParticipantsDietrich Pauls - President, CEO & DirectorJulie...

🛰️

Benzinga·1d ago

DiaMedica Therapeutics Q2 EPS $(0.19) Beats $(0.20) Estimate

DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5.56 percent decrease over losses of $(0.18) per share